💊 医薬品 A-Z 🧬 標的 🛠 ツール 📚 ガイド
全医薬品 薬物分類 治療領域 副作用
ガイド 用語集 年表
比較 薬物の体内の旅 薬物ファミリー
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tisotumab Vedotin

CHEMBL4297841 Phase 4 承認済み Antibody drug conjugate
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Tisotumab vedotin is an antibody-drug conjugate (ADC) consisting of a human monoclonal antibody targeting tissue factor (TF/CD142), conjugated via a protease-cleavable linker to monomethyl auristatin E (MMAE), a microtubule-disrupting cytotoxin. Upon binding to TF-expressing tumor cells, the ADC is internalized and MMAE is released, inducing cell cycle arrest and apoptosis; TF-expressing tumor cells also receive direct antibody-mediated cytotoxicity. It is approved for recurrent or metastatic cervical cancer and is under investigation for bladder and non-small cell lung cancers.

治療領域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Non-Small Cell Lung Cancer Prostate Cancer

作用機序

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Tisotumab vedotin is an antibody-drug conjugate (ADC) consisting of a human monoclonal antibody targeting tissue factor (TF/CD142), conjugated via a protease-cleavable linker to monomethyl auristatin E (MMAE), a microtubule-disrupting cytotoxin. Upon binding to TF-expressing tumor cells, the ADC is internalized and MMAE is released, inducing cell cycle arrest and apoptosis; TF-expressing tumor cells also receive direct antibody-mediated cytotoxicity. It is approved for recurrent or metastatic cervical cancer and is under investigation for bladder and non-small cell lung cancers.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Tisotumab Vedotin is an approved drug. It has reached clinical phase 4. It is classified as a Antibody drug conjugate.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297841. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.